本帖最后由 老马 于 2012-1-13 21:20 编辑 ! a2 Q# R; ~- x
. k! O) s8 e9 s* a# I+ X
爱必妥和阿瓦斯丁的比较
, l( q0 h3 [4 f. a' [' k( g! {
: X$ _) @9 k% h Y3 _* r$ Bhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/3 {; U1 C- F9 S3 Q" I+ ^2 Z1 H
: b! B3 Z/ `0 }) K
# ]% s5 I! z7 r7 h, P6 P" r
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
; ?; r" [% Q0 {" j3 A==================================================; Q1 s1 r7 A2 \$ c: G8 X/ V* l: B
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)' {: j5 X1 K5 ]9 k' K1 ]
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.8 ?! D9 c. n+ J& ^
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.4 r3 i- A( M' t' |9 L+ b, Q
|